ABSTRACT
Objectives Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugate vaccines (PCVs) with expanded coverage have the potential to reduce the pneumococcal disease burden among adults.
Methods Using a Markov model, we evaluated the lifetime outcomes/costs comparing 20-valent PCV (PCV20) with standard of care (SC) vaccination for prevention of CAP and IPD among adults aged ≥60 years and at-risk adults aged 18-59 years in Germany. PCV20 also was compared with sequential vaccination with 15-valent PCV (PCV15) followed by (→) PPSV23 in a scenario analysis.
Results Over the course of a lifetime (82 years), use of PCV20 vs. SC would prevent 54,333 hospitalizations, 26,368 outpatient CAP cases, 10,946 disease-related deaths yield 74,694 additional life-years (LYs), while lowering total medical costs by 363.2M €. PCV20 remained cost saving (i.e., dominant) versus SC even in numerous sensitivity analyses. In the scenario analysis, PCV20 also showed to be cost-saving compared to using PCV15→PPSV23.
Conclusions One dose of PCV20 among adults aged ≥60 years and adults aged 18-59 years with moderate- and high-risk conditions would substantially reduce pneumococcal disease, save lives, and be cost saving compared with SC.
HIGHLIGHTS
Pneumococcal disease causes significant morbidity and mortality among adults in Germany
New, higher valent vaccines have the potential to reduce disease burden and associated costs in vulnerable populations
ver a lifetime, 20-valent pneumococcal conjugate vaccine was found to be cost-saving compared with current standard of care for pneumococcal disease prevention among adults in Germany
Competing Interest Statement
Felicitas Kuehne, Josephine Friedrich, Ralf Sprenger, Christian Theilacker, Christof von Eiff, and Jeffrey Vietri are employees of Pfizer. Ernestine Mahar was an employee of Pfizer Deutschland GmbH at the time of analysis, but not at the time of publication. All of which may hold stock or stock options. Mark Atwood is an employee of Policy Analysis Inc. (PAI), which received financial support from Pfizer for this study. Katharina Achtert, Franziska Pueschner, Dominika Urbanski-Rini, and Juliane Schiller are employees of the Private Institute for Applied Health Services Research (inav), which received financial support from Pfizer for this study.
Funding Statement
The research described herein and manuscript development was supported by Pfizer Pharma GmbH and Pfizer Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Manuscript updated to clarify methods, Table 1 updated to add sources, Table 2 updated with additional sensitivity analyses, Table 3 updated with additional scenario analyses, Supplementary updated
Data Availability
All data produced in the present study are available upon reasonable request to the authors
